Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y102

Sigma-Aldrich

YC-1

powder

Synonyme(s) :

3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H16N2O2
Numéro CAS:
170632-47-0
Poids moléculaire :
304.34
Numéro MDL:
MFCD06407798
Code UNSPSC :
41106305
ID de substance PubChem :
24278782
Nomenclature NACRES :
NA.77

Forme

powder

Niveau de qualité

200

Couleur

white to yellow

Solubilité

DMSO: 10 mg/mL
H2O: insoluble

Chaîne SMILES 

OCc1ccc(o1)-c2nn(Cc3ccccc3)c4ccccc24

InChI

1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2

Clé InChI

OQQVFCKUDYMWGV-UHFFFAOYSA-N

Informations sur le gène

human ... PDE5A(8654)

Application

YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:
  • to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs)
  • to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the proliferation rate of cells with an ability to form long term colony forming units
  • to study its effect on regulating sphingosine 1-phosphate (S1P) bound to albumin induced plasminogen activator inhibitor 1 (PAI-1) expression by activating Rho/ Rho-associated protein kinase (ROCK) pathway.

Actions biochimiques/physiologiques

NO (nitric oxide)-independent activator of soluble guanylyl cyclase.
YC-1 activates soluble guanylyl cyclase and prevents platelet aggregation and vascular contraction. It has a potential to treat circulation disorders. YC-1 also has an ability to inhibit hypoxia-inducible factor 1α (HIF-1α) activity in vitro. It acts as a potential antiangiogenic anticancer agent.

Caractéristiques et avantages

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Luke Gammon et al.
PloS one, 8(4), e62493-e62493 (2013-05-03)
The glycolytic response of hypoxic cells is primarily mediated by the hypoxia inducible factor alpha (HIF-1α) but even in the presence of abundant oxygen tumours typically show high rates of glycolysis. Higher levels of HIF-1α in tumours are associated with
Jian Kong et al.
PloS one, 7(5), e37266-e37266 (2012-05-23)
The mechanism of rapid growth of the residual tumor after radiofrequency (RF) ablation is poorly understood. In this study, we investigated the effect of hyperthermia on HepG2 cells and generated a subline with enhanced viability and dys-regulated angiogenesis in vivo
Kota Wakiyama et al.
Scientific reports, 7(1), 12653-12653 (2017-10-06)
This study aimed to establish a therapeutic strategy targeting hypoxic cancer cells in gastric carcinoma (GC). YC-1 is a HIF-1α inhibitor, and we revealed that low-dose YC-1 (10 µM) suppressed HIF-1α expression, and induced hypoxia-dependent apoptosis in the GC cell line
Zong-Tao Chai et al.
PloS one, 8(10), e77957-e77957 (2013-11-07)
microRNAs (miRNAs) have been reported to regulate angiogenesis by down-regulating the expression of pro-angiogenic or anti-angiogenic factors. The aims of this study were to investigate whether miR-26a inhibited angiogenesis by down-regulating vascular endothelial growth factor A (VEGFA) and its clinical
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1
Yeo EJ, et al.
Journal of the National Cancer Institute, 95(7), 516-525 (2003)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique